Lilly (LLY.US) recommends Elpida peptide as a weight loss drug by the UK regulatory agency.
The UK's National Institute for Health and Care Excellence has officially recommended the GLP-1 drug Tirzepatide from Lilly as a weight loss medication.
The UK's drug cost-effectiveness watchdog, the National Institute for Health and Care Excellence (NICE), has formally recommended Eli Lilly and Company's GLP-1 drug Tirzepatide as a weight loss medication. The drug is sold under the names Zepbound for weight loss and Moujaro for treating type 2 diabetes.
Due to anticipated high demand, NICE had earlier stated in December that Tirzepatide would be rolled out over a three-year period, with the "highest clinical need" patients being given priority for the drug.
Related Articles
Jiangsu Chengxing Phosph-Chemicals (600078.SH): The Jiangyin factory will officially cease production fully starting from January 24, 2026.
Shareholder Park Huahui of Hicon Network Technology (301262.SZ) plans to reduce his holdings by no more than 3.60%.
HuaDian Heavy Industries (601226.SH) was awarded the first prize of the 2025 Power Innovation Award.
Jiangsu Chengxing Phosph-Chemicals (600078.SH): The Jiangyin factory will officially cease production fully starting from January 24, 2026.
Shareholder Park Huahui of Hicon Network Technology (301262.SZ) plans to reduce his holdings by no more than 3.60%.
HuaDian Heavy Industries (601226.SH) was awarded the first prize of the 2025 Power Innovation Award.
RECOMMEND
